Regeneron Among Top AI Healthcare Stocks Favored by Hedge Funds
Hedge funds are eyeing AI-powered healthcare plays, with Regeneron Pharmaceuticals emerging as a notable pick in the sector.
Regeneron Pharmaceuticals (REGN) has drawn significant attention from hedge fund managers scouting for the best artificial intelligence-driven healthcare stocks, according to a recent analysis published by Yahoo Finance. The biotech giant's integration of AI into its drug discovery and development pipeline has positioned it as a standout candidate among institutional investors seeking exposure to the intersection of technology and medicine.
Hedge funds have increasingly pivoted toward healthcare companies that leverage machine learning and AI to accelerate research timelines, reduce costs, and improve clinical trial outcomes. Regeneron, long recognized for blockbuster therapies like Dupixent and Eylea, has been expanding its computational biology capabilities, making it attractive to funds looking beyond traditional pharma metrics.
Read more Intel Stock Up 550% But Manufacturing Hurdles Remain →
The broader trend reflects a growing conviction on Wall Street that AI adoption in healthcare is not a distant promise but an active catalyst already reshaping how leading biopharmaceutical companies operate. Analysts and fund managers appear to view Regeneron's dual strength — proven commercial drugs alongside a robust AI-enhanced R&D infrastructure — as a rare combination in the current market environment.
While the source did not disclose specific hedge fund names or exact position sizes, the framing of Regeneron among the "best" AI-powered healthcare stocks suggests it ranks competitively against peers when institutional sentiment is measured. Investors tracking smart money flows in biotech will likely watch REGN closely as AI-driven drug development continues to gain momentum across the sector.
Continue reading at Yahoo Finance.
